BioDrugs

, Volume 26, Issue 3, pp 195–199

Belimumab: A Guide to Its Use in Systemic Lupus Erythematosus

  • Lesley J. Scott
  • Celeste B. Burness
  • Paul L. McCormack
Adis Drug Clinical Q&A

DOI: 10.2165/11209060-000000000-00000

Cite this article as:
Scott, L.J., Burness, C.B. & McCormack, P.L. BioDrugs (2012) 26: 195. doi:10.2165/11209060-000000000-00000

Abstract

Belimumab (Benlysta ®), a fully human recombinant IgG1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells, is indicated for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite receiving standard therapy. In multinational trials, significantly more belimumab recipients than placebo recipients achieved an SLE Responder Index response at 52 weeks.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Lesley J. Scott
    • 1
  • Celeste B. Burness
    • 1
  • Paul L. McCormack
    • 1
  1. 1.AdisAucklandNew Zealand